MGX (Metagenomi Therapeutics) Current Deferred Revenue: $11.20 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.23
GF Value $0.69
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Current Deferred Revenue?

Metagenomi Therapeutics MGX 10 Current Deferred Revenue is $11.20 Mil as of Jun. 2026. GuruFocus rates MGX with a GF Score™ of 10/100 and a GF Value™ of $0.69 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Metagenomi Therapeutics's current deferred revenue for the quarter that ended in Jun. 2026 was $11.20 Mil.

Metagenomi Therapeutics Current Deferred Revenue Related Terms

Metagenomi Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Current Deferred Revenue Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
16.04 33.94 48.07 22.76 8.70

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.94 12.90 8.70 9.31 11.20
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $11.20 Mil mean?
Metagenomi Therapeutics (MGX) has a Current Deferred Revenue of $11.20 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Current Deferred Revenue too high?
Metagenomi Therapeutics' current Current Deferred Revenue is $11.20 Mil. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Current Deferred Revenue compare to BYSI and EXOZ?
Metagenomi Therapeutics' Current Deferred Revenue of $11.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Current Deferred Revenue is $11.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Metagenomi Therapeutics (MGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $1.23 — trading 78.3% above its estimated fair value. The current Current Deferred Revenue is $11.20 Mil. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Current Deferred Revenue is $11.20 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metagenomi Therapeutics (MGX) Overvalued in 2026?

Based on GuruFocus' analysis, Metagenomi Therapeutics stock appears to be overvalued. The current stock price of $1.23 is trading 78.3% above its estimated GF Value™ of $0.69. GuruFocus considers Metagenomi Therapeutics to be Significantly Overvalued.

Key valuation signals for MGX:

  • Current Deferred Revenue: $11.20 Mil
  • GF Value™: $0.69 vs. price of $1.23 (78.3% above fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the MGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.23
Price
$0.69
GF Value